3Fava GA, Fabbri S, Sonino N, Residual symptoms in depression: an emerging therapeutic target. Prog Neuropsyehopharmaeol Biol Psychiatry, 2002, 26:1019-1027.
4Paykel ES. Remission and residual symptomatology in major depression. Psychopathology, 1998, 31:5-14.
5McIntyre RS, O'Donovan C. The human cost of not achieving full remission in depression. Can J Psychiatry, 2004, 49 ( 3 Suppl 1 ) : 10S-16S.
6Stewart WF, Ricci JA, Chee E, et al. Cost of lost productive work time among US workers with depression. JAMA, 2003,289:3135- 3144.
7Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord, 1998, 50 ( 2/3 ) :97-108.
8Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine -controlled trial. Eur Neuropsychopharmacol, 2004, 14:457-470.
9Zhang W, Perry KW, Wong DT, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology, 2000, 23:250-262.
10Fava GA, Rafanelli C, Grandi S, et al. Prevention of recurrent depression with cognitive behavioral therapy: preliminary findings. Arch Gen Psychiatry, 1998, 55:816-820.
6Ingram S,Maher V,Bennett K,et al.The effect of cardiopnli-monary resuscitation Training on psyehological variables of eardiac rchabilitation patienle[J].Resuscita-Tion,2006,71(1):89-96.
